Ventripoint Diagnostics Ltd (VPTDF) 0.1049

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ventripoint Diagnostics Ltd (VPTDF) 0.1049 $VPTDF

Ventripoint Announces New Director and Provides Corporate Update
Marketwired - Wed Nov 04, 7:57AM CST
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Corporation" (TSX VENTURE: VPT) announces that Dave Willis has joined the Board of Directors of the Corporation. Mr. Willis is an expert in the development and international sales of ultrasound equipment. Until recently, he was Vice President Competitive Strategy and Product Innovation at SonoSite-Fujifilm Ultrasound, where he was responsible for design input, launch and global training of 4 major product releases. He also served as Vice President of Sales and Marketing the Americas for Ultrasonix Medical Corp, where he managed sales forces in Canada, U.S.A, and South America.
VPT.VN: 0.150 (-0.010)

IIROC Trade Resumption - VentriPoint Diagnostics Ltd.
Newsfile Corp - Fri Oct 23, 8:31AM CDT
Trading resumes in:

Ventripoint Corporate Update
Marketwire Canada - Fri Oct 23, 8:24AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company" (TSX VENTURE:VPT) announces that subsequent to the departure of Mr. Jim Bodtke, the Board of Directors of the Company has accepted the resignations of Jeff Jellum, Director of Operations and Huy Le, Regional Account Manager.
VPT.VN: 0.150 (-0.010)

IIROC Trade Halt - VentriPoint Diagnostics Ltd.
Newsfile Corp - Wed Oct 21, 10:36AM CDT
The following issues have been halted by IIROC:

Ventripoint Announces Results of Annual Shareholders' Meeting and Engagement of Investor Relations Firm
Marketwired - Thu Oct 15, 6:32AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company" (TSX VENTURE: VPT) announces that at its Annual General Meeting on October 13, 2015 the shareholders elected Dr. George Adams, Mr. Danny Dalla-Longa, Dr. Alan Rabinowitz and Mr. Treuman Katz as Directors of the Company. They further approved the Incentive Stock Option plan and gave authority to the Board of Directors to undertake a share consolidation if it deems the consolidation is in the best interests of Ventripoint. BDO was appointed as auditors of the Company for the next year.
VPT.VN: 0.150 (-0.010)

Ventripoint Announces Development of New VMS(TM) Products and Enhanced Capabilities as Featured at ASE 2015
Marketwired - Thu Jun 25, 7:02AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) is pleased to announce that a new platform design of the VMS(TM) workstation will be made available to select markets with complete availability expected in the 4th quarter of 2015. The new platform, branded VMS-Plus(TM), was the Company's featured product at the American Society of Echocardiography Scientific Session (ASE 2015) held in Boston last week.
VPT.VN: 0.150 (-0.010)

Ventripoint Receives Marketing Clearance from the FDA to Expand the Use of the VMS Heart Analysis System
Marketwired - Tue May 26, 7:31AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) is pleased to announce that it has received Marketing Clearance from the U.S. Food & Drug Administration ("FDA" for the expanded Indications for Use of its VMS(TM) product which states; "The VMS system is indicated for use where RV (right ventricle) volumes and ejection fractions are warranted or desired".
VPT.VN: 0.150 (-0.010)

Latest Clinical Study Finds Ventripoint VMS(TM) Offers Consistent and Accurate Results Regardless of Examiner
Marketwired - Mon Apr 27, 7:54AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) announces that a group led by Dr. Daniel Knight in London, United Kingdom, has demonstrated further the accuracy of Ventripoint's VMS(TM) heart analysis system.
VPT.VN: 0.150 (-0.010)

Ventripoint Announces Response to Interactive Review for Recent 510(k) Submission to FDA
Marketwired - Wed Apr 08, 7:02AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) is pleased to announce that it has completed the first round of review concerning the most recent 510(k) submission to the U.S. Food & Drug Administration ("FDA". On March 26th, 2015, Ventripoint received a request for additional information via Interactive Review. The Company responded promptly and delivered the requested information to the FDA for evaluation.
VPT.VN: 0.150 (-0.010)

Ventripoint Announces Distribution Partner for Military and VA Medical Centers
Marketwired - Mon Mar 30, 7:34AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Corporation" (TSX VENTURE: VPT) is pleased to announce that is has appointed PYP Enterprises LLC (PYP) to be the exclusive distributor to the US military hospitals including the VA hospitals.
VPT.VN: 0.150 (-0.010)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 225

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 466

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 212

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 0

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 0

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 349

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 277

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 284

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 42

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading

Top 5 Most Recently Viewed Articles

Lawsuit Filed Alleging Eye Injury from Ozempic Use

Updated Category News Views 165

Parker Waichman LLP Takes Action Against Drug Manufacturer Parker Waichman, a prominent national law firm, is actively filing lawsuits for individuals who assert that they developed NAION after using Novo Nordisk's medications, Ozempic or Wegovy. The firm recently initiated a case for a Florida resident who experienced this severe eye condition after using Ozempic....

Continue Reading
C.H. Robinson Prepares for Upcoming Earnings Conference Call

Updated Category News Views 151

C.H. Robinson's Upcoming Earnings Release and Conference Call C.H. Robinson Worldwide, Inc. (Nasdaq: CHRW), a leading logistics provider, has announced significant plans for its upcoming earnings release. The company is scheduled to share its third quarter 2024 results post market close. On this important day, the company will hold a conference call to delve into the...

Continue Reading
PayPal Surges 14% After Exciting Partnership with OpenAI

Updated Category News Views 173

PayPal's Innovative Partnership with OpenAI Shares of PayPal Holdings Inc (NASDAQ: PYPL) experienced a notable increase of 14.38% in pre-market trading. This rise was sparked by the recent announcement of a deal between the payments giant and OpenAI. This partnership focuses on integrating PayPal's digital wallet into the popular AI platform, ChatGPT. Enabling...

Continue Reading
Unlocking the Future of Ridesharing: Uber and Nvidia's Game Changer

Updated Category News Views 199

Introduction to the Partnership In an exciting development, Uber Technologies Inc (NYSE: UBER) has announced a strategic partnership with Nvidia Corp (NASDAQ: NVDA) aimed at leveraging artificial intelligence (AI) to enhance ridesharing and autonomous vehicle technology. Analyst Justin Post from BofA Securities has enthusiastically maintained a Buy rating on Uber’s...

Continue Reading
Exploring the Future of Organic Infant Formula Market Growth

Updated Category News Views 275

Overview of Organic Infant Formula Market Growth The Organic Infant Formula market has seen remarkable expansion, indicating a shift in parental preferences towards health-conscious choices for their young ones. The market, which had a valuation of USD 20.8 billion in the recent past, is expected to reach an impressive USD 36.04 billion by 2032. This growth trajectory...

Continue Reading